Study:
Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML)
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. It is not yet
known if chemotherapy is more effective with or without monoclonal antibody therapy for
acute myelogenous leukemia.
Purpose:
Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without monoclonal antibody therapy in treating patients who have refractory or
relapsed acute myelogenous leukemia.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Leukemia |
Biological: lintuzumab
Drug: cytarabine
Drug: etoposide
Drug: mitoxantrone hydrochloride |
Phase 3 |
Verified by
Facet Biotech
February, 2010
Sponsored by: Facet Biotech
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00006045
Study Type: Interventional
Study Design: Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Daniel Levitt, MD, PhD., Study Chair